NASDAQ:PCVX

Vaxcyte Competitors

$23.62

-2.21 (-8.56 %)

(As of 03/4/2021 12:00 AM ET)

Add

Compare

Today's Range

$23.42

Now: $23.62▼

$26.19

50-Day Range

$23.56

MA: $25.29▼

$27.90

52-Week Range

$17.80

Now: $23.62▼

$58.47

Volume397,419 shs

Average Volume362,415 shs

Market Capitalization$1.20 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Vaxcyte (NASDAQ:PCVX) Vs. IOVA, CBPO, ALLO, BEAM, RLAY, and SWTX

Should you be buying PCVX stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Vaxcyte, including Iovance Biotherapeutics (IOVA), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Beam Therapeutics (BEAM), Relay Therapeutics (RLAY), and SpringWorks Therapeutics (SWTX).

Vaxcyte vs. Iovance Biotherapeutics Stock

Iovance Biotherapeutics (NASDAQ:IOVA) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Profitability

This table compares Iovance Biotherapeutics and Vaxcyte's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	N/A	-50.64%	-45.64%
Vaxcyte	N/A	N/A	N/A

Institutional & Insider Ownership

94.6% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 74.1% of Vaxcyte shares are owned by institutional investors. 9.9% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Iovance Biotherapeutics and Vaxcyte's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	N/A	N/A	$-197,560,000.00	($1.59)	-19.98
Vaxcyte	N/A	N/A	$-50,270,000.00	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations for Iovance Biotherapeutics and Vaxcyte, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	0	2	8	0	2.80
Vaxcyte	0	0	4	0	3.00

Iovance Biotherapeutics presently has a consensus target price of $50.10, indicating a potential upside of 57.70%. Vaxcyte has a consensus target price of $48.00, indicating a potential upside of 103.22%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts clearly believe Vaxcyte is more favorable than Iovance Biotherapeutics.

Summary

Vaxcyte beats Iovance Biotherapeutics on 5 of the 8 factors compared between the two stocks.

Vaxcyte vs. China Biologic Products Stock

Vaxcyte (NASDAQ:PCVX) and China Biologic Products (NASDAQ:CBPO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Vaxcyte and China Biologic Products' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	N/A	N/A
China Biologic Products	27.43%	8.32%	7.64%

Insider and Institutional Ownership

74.1% of Vaxcyte shares are owned by institutional investors. Comparatively, 34.8% of China Biologic Products shares are owned by institutional investors. 2.7% of China Biologic Products shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Vaxcyte and China Biologic Products' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	$-50,270,000.00	N/A	N/A
China Biologic Products	$503.70 million	9.23	$138.81 million	$4.28	27.58

China Biologic Products has higher revenue and earnings than Vaxcyte.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vaxcyte and China Biologic Products, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	0	0	4	0	3.00
China Biologic Products	0	0	0	0	N/A

Vaxcyte presently has a consensus price target of $48.00, indicating a potential upside of 103.22%. Given Vaxcyte's higher probable upside, analysts plainly believe Vaxcyte is more favorable than China Biologic Products.

Summary

China Biologic Products beats Vaxcyte on 6 of the 9 factors compared between the two stocks.

Vaxcyte vs. Allogene Therapeutics Stock

Vaxcyte (NASDAQ:PCVX) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Vaxcyte and Allogene Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	N/A	N/A
Allogene Therapeutics	N/A	-27.59%	-24.97%

Insider and Institutional Ownership

74.1% of Vaxcyte shares are owned by institutional investors. Comparatively, 59.9% of Allogene Therapeutics shares are owned by institutional investors. 31.3% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Vaxcyte and Allogene Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	$-50,270,000.00	N/A	N/A
Allogene Therapeutics	N/A	N/A	$-184,590,000.00	($1.83)	-17.72

Analyst Recommendations

This is a summary of current recommendations and price targets for Vaxcyte and Allogene Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	0	0	4	0	3.00
Allogene Therapeutics	0	3	13	0	2.81

Vaxcyte presently has a consensus price target of $48.00, indicating a potential upside of 103.22%. Allogene Therapeutics has a consensus price target of $52.0833, indicating a potential upside of 60.60%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than Allogene Therapeutics.

Summary

Vaxcyte beats Allogene Therapeutics on 6 of the 8 factors compared between the two stocks.

Vaxcyte vs. Beam Therapeutics Stock

Vaxcyte (NASDAQ:PCVX) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Vaxcyte and Beam Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	N/A	N/A
Beam Therapeutics	-529,075.00%	-103.41%	-48.05%

Insider and Institutional Ownership

74.1% of Vaxcyte shares are owned by institutional investors. Comparatively, 49.8% of Beam Therapeutics shares are owned by institutional investors. 0.7% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Vaxcyte and Beam Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	$-50,270,000.00	N/A	N/A
Beam Therapeutics	$20,000.00	212,996.07	$-78,330,000.00	($14.05)	-5.23

Vaxcyte has higher earnings, but lower revenue than Beam Therapeutics.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vaxcyte and Beam Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	0	0	4	0	3.00
Beam Therapeutics	0	3	3	0	2.50

Vaxcyte presently has a consensus price target of $48.00, indicating a potential upside of 103.22%. Beam Therapeutics has a consensus price target of $96.00, indicating a potential upside of 30.63%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than Beam Therapeutics.

Summary

Vaxcyte beats Beam Therapeutics on 8 of the 10 factors compared between the two stocks.

Vaxcyte vs. Relay Therapeutics Stock

Vaxcyte (NASDAQ:PCVX) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Vaxcyte and Relay Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	N/A	N/A
Relay Therapeutics	N/A	N/A	N/A

Insider and Institutional Ownership

74.1% of Vaxcyte shares are owned by institutional investors. Comparatively, 98.4% of Relay Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Vaxcyte and Relay Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	$-50,270,000.00	N/A	N/A
Relay Therapeutics	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Vaxcyte and Relay Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	0	0	4	0	3.00
Relay Therapeutics	0	1	5	0	2.83

Vaxcyte presently has a consensus price target of $48.00, indicating a potential upside of 103.22%. Relay Therapeutics has a consensus price target of $57.40, indicating a potential upside of 43.54%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than Relay Therapeutics.

Vaxcyte vs. SpringWorks Therapeutics Stock

Vaxcyte (NASDAQ:PCVX) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Vaxcyte and SpringWorks Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	N/A	N/A
SpringWorks Therapeutics	N/A	-24.48%	-23.58%

Insider and Institutional Ownership

74.1% of Vaxcyte shares are owned by institutional investors. Comparatively, 76.3% of SpringWorks Therapeutics shares are owned by institutional investors. 51.2% of SpringWorks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Vaxcyte and SpringWorks Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	$-50,270,000.00	N/A	N/A
SpringWorks Therapeutics	N/A	N/A	$-58,310,000.00	($3.55)	-19.52

Analyst Recommendations

This is a summary of current recommendations and price targets for Vaxcyte and SpringWorks Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	0	0	4	0	3.00
SpringWorks Therapeutics	0	0	3	0	3.00

Vaxcyte presently has a consensus price target of $48.00, indicating a potential upside of 103.22%. SpringWorks Therapeutics has a consensus price target of $91.00, indicating a potential upside of 31.31%. Given Vaxcyte's higher probable upside, analysts plainly believe Vaxcyte is more favorable than SpringWorks Therapeutics.

Summary

Vaxcyte beats SpringWorks Therapeutics on 5 of the 7 factors compared between the two stocks.